VXRT - Vaxart Inc logo

Vaxart Inc

VXRT
Rev 272xtop 1%5Y
Compare VXRT Hold

Vaxart Inc. develops oral recombinant protein vaccines using its proprietary platform. Its pipeline includes vaccines for norovirus, COVID-19, seasonal influenza, and human papillomavirus, targeting various viral strains and diseases.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 30 years ago โ†’$1today

Score Overview

1 Year
Score
Net Growth136.35%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth2.45%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score7.6
Net Growth154.76%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth272x
Rev Trend80%
Revenue Consistencyโ€”
All Time
Score
Net Growth314.30%
Net Trend50%
Net Income Consistency
Rev Growth58x
Rev Trend63%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Vaxart Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. VXRT does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 0.45โ€”
1 Year2025-09-29
$ 0.3624.72%
5 Years2021-09-29
$ 8.02-94.40%
10 Years2016-09-29
$ 21.23-97.89%
20 Years2006-09-29
$ 342.34-99.87%
30 Years1996-09-27
$ 718.15-99.94%
All Time2018-02-12
$ 8.80-94.90%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 243M$ 38M$ 63M
2025$ 237M$ 16M$ 63M
2024$ 28M-$ 66M$ 51M
2023$ 7M-$ 82M$ 39M
2022$ 107K-$ 107M$ 93M
2021$ 892K-$ 70M$ 166M
2020$ 4M-$ 32M$ 126M
2019$ 9M-$ 18M$ 13M
IPO2018$ 4M-$ 18M$ 11M
VXRT - Vaxart Inc logo

Vaxart Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 4M to $ 237M and net income went from -$ 32M to $ 16M. Revenue increased in 4 of those 5 years; net income in 4.

Vaxart Inc currently holds a 5-year HDB Score of 7.6 out of 10. How the HDB Score is calculated.

Membership

Explore VXRT with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies